-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tirofiban hydrochloride monohydrate is a pharmaceutical compound that is used in the treatment of acute coronary syndrome, a group of conditions that include heart attacks and unstable angina.
This medication works by preventing platelets from sticking together and forming clots, which can cause blockages in the coronary arteries.
In this article, we will take a closer look at tirofiban hydrochloride monohydrate and its use in the chemical industry.
Background
Tirofiban hydrochloride monohydrate is a potent and selective glycoprotein IIb/IIIa inhibitor.
It is synthesized by recombinant DNA technology using a baculovirus expression vector, and is purified by several chromatographic techniques.
The chemical formula for tirofiban hydrochloride monohydrate is C81H115N15O18S3.
It has a molecular weight of 1503.
9 Da and a solubility of 2.
7 mg/mL in water.
Uses
Tirofiban hydrochloride monohydrate is used in the treatment of acute coronary syndrome, a condition that can lead to heart attacks and unstable angina.
It works by inhibiting the action of glycoprotein IIb/IIIa, a protein found on the surface of platelets.
By inhibiting this protein, tirofiban hydrochloride monohydrate prevents platelets from sticking together and forming clots in the coronary arteries.
This helps to improve blood flow to the heart and reduce the risk of further heart damage.
In addition to its use in the treatment of acute coronary syndrome, tirofiban hydrochloride monohydrate has also been studied for its potential use in other medical conditions.
These include the prevention of blood clots in patients undergoing percutaneous coronary intervention, the prevention of deep vein thrombosis and pulmonary embolism, and the reduction of thrombotic burden in patients with myocardial infarction.
Manufacturing
The production of tirofiban hydrochloride monohydrate involves several steps, including the cultivation of the baculovirus expression vector, the purification of the recombinant protein, and the synthesis of the hydrochloride salt.
First, the baculovirus expression vector is cultivated in insect cells.
This vector contains the genetic information for the production of tirofiban hydrochloride monohydrate.
The insect cells are then harvested and the recombinant protein is extracted and purified using several chromatographic techniques.
Next, the purified protein is subjected to a series of chemical reactions that result in the formation of tirofiban hydrochloride monohydrate.
This involves the addition of a hydrochloride salt to the protein, which results in the formation of the final product.
Quality Control
The quality of tirofiban hydrochloride monohydrate is controlled by several methods, including chromatographic analysis and mass spectrometry.
These methods are used to ensure that the final product meets the required specifications for purity, potency, and identity.
In addition, the manufacturing process for tirofiban hydrochloride monohydrate is subject to strict regulations and guidelines.
This ensures that the product is safe and effective for use in patients.
Availability
Tirofiban hydrochloride monohydrate is available in several countries under different trade names.
In the United States, it is marketed under the trade name Aggrastat.
In Europe, it is marketed under the trade name GiTyp